Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Bridge Medicines manages 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This single matter is assigned to 1 distinct examiner and 1 distinct art unit. The portfolio currently reflects a focused prosecution effort on a single biotechnological innovation. This concentration simplifies the management of the company's intellectual property by limiting the number of points of contact at the USPTO.
The busiest examiner for this company is HOWELL, THEODORE R, who is responsible for 1 pending office action. This represents the entirety of the pending workload. Practitioners should focus on the specific preferences of this 1 examiner, as the entire current portfolio is concentrated within a single art unit. The procedural path for this application will be defined by the standards of the Biotechnology & Pharmaceuticals technology area.
Because there is only 1 pending office action, the company's success in the patent office is currently tied to this single matter. There are no other active applications to provide a baseline for comparison within the portfolio. Practitioners should monitor the specific allowance rates and response times for HOWELL, THEODORE R to better anticipate the timeline for this 1 distinct art unit.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HOWELL, THEODORE R | 1 | 66.9% | +25.1% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18560663 | C-LINKED INHIBITORS OF ENL/AF9 YEATS | HOWELL, THEODORE R | 29d overdue |
| Art Unit | Apps |
|---|---|
| 1628 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18560663 | C-LINKED INHIBITORS OF ENL/AF9 YEATS | HOWELL, THEODORE R | 1628 | §112 | Final Rejection | 29d overdue | Pending | Nov 13, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialBridge Medicines has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Theodore R Howell has the most, with 1 of Bridge Medicines's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
